Oscar Clinical Guidelines: Pharmacy

hearts
Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Oscar may delegate utilization management decisions of certain services to third-party delegates who may develop and adopt their own clinical criteria. The clinical guidelines are applicable to all commercial policies. Coverage of services is subject to the terms, conditions, limitations of a member’s policy and applicable state and federal law. Please reference the member’s policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits) or to confirm coverage contact 855-672-2755 for Oscar Plans and 855-672-2789 for Cigna+Oscar Plans. Looking for Medical Guidelines? Click here.

Upcoming Policy Changes

    • Effective 10/1/2025
      • armodafinil (Nuvigil) (PG036_v7)
      • Avonex (interferon beta-1a) (PG218)_v2
      • Bafiertam (monomethyl fumarate) (PG219)_v2
      • Benzodiazepines for Acute Repetitive Seizures or Seizure Clusters (PG254)_v3
      • Betaseron (interferon beta-1b) (PG220)_v2
      • Briumvi (ublituximab) (PG134)_v5
      • Casgevy (exagamglogene autotemcel) (CG113)_v3
      • Collagenase Ointment (Santyl) (PG141)_v3
      • Dalfampridine (Ampyra) (PG217)_v2
      • Dapsone 7.5% topical Gel (Aczone) (PG214)_v2
      • Dimethyl Fumarate (Tecfidera) (PG222)_v2
      • Eohilia (budesonide) (PG216)_v2
      • Eucrisa (crisaborole) (PG023)_v7
      • Extavia (interferon beta-1b) (PG223)_v2
      • Ezetimibe (Zetia) (PG073)_v7
      • Fingolimod (Gilenya, Tascenso ODT) (PG224)_v2
      • Glatiramer Acetate (Copaxone, Glatopa) (PG221)_v3
      • Journavx (suzetrigine) Quantity Limit Exceptions Criteria (PG260)_v1
      • Kesimpta (ofatumumab) (PG225)_v3
      • Lemtrada (Alemtuzumab) (PG226)_v2
      • Lidoderm (lidocaine) 5% Transdermal Patch (PG124)_v4
      • Lokelma (sodium zirconium cyclosilicate) (PG143)_v3
      • Mavenclad (cladribine) (PG227)_v2
      • Mayzent (siponimod) (PG228)_v2
      • Mesalamine DR 800 (Asacol HD) (PG024)_v7
      • Modafinil (Provigil) (PG035)_v7
      • Neffy (epinephrine nasal spray) (PG243)_v2
      • Ocrelizumab (Ocrevus, Ocrevus Zunovo) (PG235)_v4
      • Omega-3-acid ethyl esters (Lovaza) (PG005)_v7
      • Plegridy (peginterferon beta-1a) (PG229)_v2
      • Ponvory (ponesimod) (PG230)_v2
      • Prenatal Vitamins Zero Copay Exception-REG (PG258)_v1
      • Quantity Limit Exception Criteria (PG200)_v2
      • Rebif (interferon beta-1a) (PG231)_v2
      • Rezdiffra (resmetirom) (PG198)_v2
      • Rosuvastatin (Crestor) (PG006)_v8
      • Sancuso (granisetron) Patch (PG007-REG)_v7
      • Sancuso (granisetron) Patch (PG007)_v7
      • Teriflunomide (Aubagio) (PG232)_v2
      • Tevimbra (tislelizumab) (PG210)_v2
      • Veozah (fezolinetant) (PG215)_v2
      • Vumerity (diroximel fumarate) (PG233)_v2
      • Zelsuvmi (berdazimer topical gel, 10.3%) (PG201)_v2
      • Zeposia (ozanimod) (PG234)_v3

    Pharmacy Guidelines

                                                                                                                                                                                                                                                                                                                                                                        Adopted Guidelines